Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter--still a dilemma? by Hegi, M.E. & Stupp, R.
   
 
 
 
 
Serveur Acade´mique Lausannois SERVAL serval.unil.ch
Author Manuscript
Faculty of Biology and Medicine Publication
This paper has been peer-reviewed but does not include the final publisher
proof-corrections or journal pagination.
Published in final edited form as:
Title: Withholding temozolomide in glioblastoma patients with
unmethylated MGMT promoter–still a dilemma?
Authors: Hegi ME, Stupp R
Journal: Neuro-oncology
Year: 2015 Nov
Issue: 17
Volume: 11
Pages: 1425-7
DOI: 10.1093/neuonc/nov198
In the absence of a copyright statement, users should assume that standard copyright protection applies, unless the article contains
an explicit statement to the contrary. In case of doubt, contact the journal publisher to verify the copyright status of an article.
1  
Withholding TMZ in GBM patients with unmethylated MGMT – still a dilemma ? 
 
Monika E. Hegi and Roger Stupp 
 
Neuroscience Research Center, Service of Neurosurgery, Lausanne University 
Hospital, Lausanne (CHUV) (MEH); Department of Oncology, University Hospital 
Zurich, Zurich, Switzerland 
 
Corresponding author: Monika E. Hegi, Department of Clinical Neurosciences, CHUV 
CLE C306, chemin des Boveresses 155, 1066 Epalinges, Switzerland 
(Monika.Hegi@chuv.ch) 
 
 
Ten years ago we established methyl-guanin methyl transferase (MGMT) gene 
promoter methylation as the first predictive marker in neuro-oncology, and the 
strongest prognostic factor for treatment outcome in newly diagnosed glioblastoma 
(GBM). But rather than embracing a marker that allows identification and selection of 
patients likely to derive some benefit from the addition of alkylating agent 
chemotherapy, we have been challenging the validity of the findings, are striving for 
the one and perfect molecular test and treat the majority of patients with 
temozolomide (TMZ) chemotherapy irrespective of the tumors MGMT status. Isn’t the 
data convincing enough, or is it the lack of effective alternative treatments to be 
offered to patients with an unmethylated MGMT ?  
 
Following a large body of mechanistic evidence for the role of MGMT in repairing 
lesions of alkylating agents, MGMT expression has been advanced as a resistance 
factor in glioma in the nineties. Subsequently in a seminal work by Esteller and 
colleagues a correlation with promoter methylation of the MGMT gene was 
demonstrated in an analysis of samples from patients treated in Spain with 
chemotherapy comprising the alkylating agent carmustine (BCNU) 1. We confirmed 
this observation in an unplanned analysis of patients treated within our phase II trial 
with upfront TMZ 2. In 2005 finally, our retrospective analysis of prospectively treated 
patients within a randomized phase III trial demonstrated a clear predictive value of 
MGMT promoter methylation status 3. Since, numerous additional trials have 
consistently demonstrated the prognostic effect of the MGMT status, but as all 
patients are now receiving upfront TMZ chemotherapy, the predictive value cannot 
be evaluated again. The one exception is elderly glioblastoma patients where the 
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relative benefit of adding chemotherapy was of lesser magnitude. Two randomized 
trials compared single agent TMZ chemotherapy versus radiotherapy (RT) 4,5. In this 
more fragile patient population it was shown that treating MGMT unmethylated 
tumors with TMZ was detrimental, while patients with methylated tumors fared best if 
treated with TMZ (even in the absence of radiotherapy). These two trials confirm the 
predictive value of the MGMT status. Together, the data allows the conclusion that 
alkylating agent chemotherapy is of marginal benefit, if any for patients with an 
MGMT unmethylated GBM.  
By continuing to treat the majority of MGMT unmethylated patients with TMZ 
chemotherapy we are missing an opportunity to do better. Innovative treatment 
approaches, novel agents in combination with radiotherapy may provide a better 
chance for improved outcome than sticking to an agent with marginal activity. From 
the patient’s point of view it may be perceived as “wasting the last opportunity” for 
trying a potentially efficacious new agent. Evidently this patient population would 
benefit most from drugs with other mechanisms of action. To date, only a few trials 
have selected patients and assigned treatments according to the MGMT promoter 
status 6-9.  
 
Adding a new drug or agent on top of the previously established combined modality 
regimen may cause undue toxicity or drug interaction, thus requiring dose reduction 
and treatment with potentially subtherapeutic doses. As an example, adding 
polygulatmated paclitaxel to the combination of TMZ/RT lead to early discontinuation 
due to prohibitive toxicity 10, but incited a follow-up trial in MGMT unmethylated 
patients only, omitting TMZ during RT (www.clinicaltrials.gov: NCT01402063). Still, 
patients with an unmethylated MGMT promoter are in greatest need for improved 
treatments, and may benefit from the opportunity to replace TMZ by novel agents. In 
a randomized EORTC trial for patients with an unmethylated MGMT promoter only; 
temsirolimus was combined with RT followed by temsirolimus maintenance and 
compared to standard TMZ/RT TMZ. Similarly, Herrlinger and colleagues 
randomized patients with an unmethylated MGMT promoter to either standard 
TMZ/RTTMZ, or RT combined with irinotecan and bevacizumab followed by 
maintenance irinotecan/bevacizumab. Although both trials failed to show improved 
outcome as compared to the standard, it is important to note, that dropping TMZ was 
not detrimental (Table 1).  
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Treatment selection according to a molecular marker is intimately dependent on the 
validity and reproducibility of the molecular test. Standardizing the MGMT assay and 
determining the optimal cutoff based on outcome prediction have been a challenge. It 
is obvious that choice of methodology, and quantity and quality of the sample may 
yield different limits of detection and levels of precision for prediction. Of note, unlike 
a mutation that is present or absent, promoter methylation creates a pattern 
recognized by so called methyl-binding proteins, which are relevant for inhibition of 
expression. These patterns are identified by different means depending on the 
methodology. This can result in some discrepancies of classification, affecting mostly 
samples with incomplete methylation. However, like for any test in medicine, 
appropriate validation is required, including but not limited to reproducibility and 
association with outcome in an independent prospective cohort. Prospective testing 
in the trials reported earlier has been performed centrally using a quantitative 
methylation specific PCR assay that is commercially available 11. In this assay the 
technical cutoff between methylated and unmethylated is set at the nadir of the 
bimodal distribution of the methylated MGMT measured (ratio with a normalizing 
gene) in a large population of samples. Evidently, there is a grey zone around the 
cutoff that can be approximated by a confidence interval. In two of the trials dropping 
TMZ 8,9 the lower bound of the 95% confidence interval was used to select 
unmethylated patients (cutoff with a “safety margin”), in order to avoid withholding 
TMZ from a patient who could potentially profit. The in and outs of MGMT testing 
have been reviewed extensively elsewhere 12.  
Additional biomarkers are required for appropriate testing of new targeted drugs 
allowing for enrichment of the potentially sensitive patient population. However, the 
frequency of a potentially druggable target may be so low (e.g. 3% for FGFR3-
TACC3 fusions 13) that conducting prospective and controlled clinical trials is 
practically almost impossible. Quality assurance and the paucity of material available 
in the brain require platforms that will provide an array of biomarkers, rather than 
individual tests. 
Patients with unmethylated GBM are in need for better treatments, and this 
population not only offers the opportunity to test novel treatments, but actually require 
more than others that they are offered innovative therapies right from the diagnosis of 
a GBM. The extended experience of the predictive value of the MGMT status in 
GBM, and the reassuring first results from trials selecting patients with an 
unmethylated MGMT for experimental therapy omitting TMZ, provide sufficient 
confidence for such an adapted trial designs. Recruiting patients according to their 
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MGMT status opens opportunities for innovative new therapies not limited by the 
treatment scheme of TMZ and respective toxicity. This will a llow focusing on new 
drugs  -  which need to be developed together with their proper biomarkers. 
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Table 1: Outcome of MGMT unmethylated glioblastoma 
 
Trial name  
 experimental regimen 
Publicatation 
year/ref. 
Median Overall Survival [months] 
  Standard arm: Experimental arm: 
  TMZ/RTTMZ TMZ/RT + novel agent 
RT + novel 
agent 
EORTC 26981  
 RT alone 
2005 3  
12.6 
 
 
 
11.8 * 
Glarius  
 Beva/RT  
2014 9  
17.3 
  
16.6 
EORTC 26082:  
 Temsirolimus 
2014 8  
16 
  
14.8 
CORE  
Cil (2x/wk)/TMZ/RTCil/TMZ 
20157  
13.4 
 
16.3 
 
Cil (5x/wk)/TMZ/RTCil/TMZ   14.5  
RTOG 0525 † 
 TMZ/RT  TMZ (21/28d) 
2012 14  
16.6 
 
15.4 
 
RTOG 0825†  
 Beva/TMZ/RT  beva/TMZ 
2014 15  
14.6 
 
14.0 
 
AvaGlio†  
 Beva/TMZ/RT  beva/TMZ 
2014 16  
16.7 
 
16.8 
 
     
† subgroup of MGMT unmethylated tumors;  * RT alone 
RT, radiotherapy; TMZ, temozolomide; beva, bevacizumab; cil, cilengitide 
EORTC, European Organisation for Research and Treatment of Cancer; RTOG, Radiation Therapy Oncology 
Group   
